Core Viewpoint - Hyperscale Data, Inc. has entered into a Securities Purchase Agreement for up to $100 million in financing from Ault & Company, Inc., which will involve the issuance of Series H Convertible Preferred Stock to support expansion and operational needs [1][3][4]. Financing Details - The financing will involve the issuance of up to $100 million in Series H Convertible Preferred Stock, which will be senior to all other classes of preferred stock except for Series C and Series G [1][2]. - Each Preferred Share has a stated value of $1,000 and can be converted into Common Stock at a conversion price that is the greater of $0.10 or a price based on the market conditions [2]. - The Preferred Shares will pay an annual dividend of 9.5%, which may be paid in shares of Class A Common Stock during the first two years [2]. Use of Proceeds - Proceeds from the financing will be allocated for the expansion of the MI data center, repayment of outstanding debts, and general working capital [3]. Market Perception - The willingness of Ault & Company to invest an additional $100 million indicates a belief that the market has undervalued Hyperscale Data, as the conversion price of the Preferred Shares is higher than the current market price [4]. Transaction Conditions - The Agreement allows for multiple closings through December 31, 2026, subject to customary closing conditions, regulatory, and stockholder approvals [5]. - The conversion of the Preferred Shares is subject to conditions that include receiving financing by Ault & Company [5]. Company Overview - Hyperscale Data operates a data center through its subsidiary Sentinum, focusing on digital asset mining and services for the AI ecosystem [9]. - The company is also involved in acquiring undervalued businesses and disruptive technologies through its subsidiary Ault Capital Group [9].

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an ex ...